MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell and gene therapies. Their core ExPERT ATx, sTX, GTx, and VLx tools use their proprietary technology called Flow Electroporation, which has been optimized for safe and efficient cell engineering.
The medical sector company has enabled biotechnology companies to develop and bring breakthrough treatments to the market. Maxcyte’s technology helped Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) to develop the world's first FDA-approved gene-editing treatment for sickle cell disease (SCD), Casgevy.
